Welcome to YHEC’s publication hub

Our latest research, all in one place. Browse our collection of journal articles, reports and conference proceedings to see how we’re contributing to HEOR research. Remember to: 

  • Filter by service, therapeutic area, or geography to narrow your results.
  • Search directly for keywords or specific titles to find what you need instantly.
Peer-reviewed publication

Cost-Effectiveness of an Absorbable Antibacterial Envelope for Infection Control in Cardiac Implantable Electronic Device Procedures in Spain

YHEC authors: Elana Greaves, Dani Afonso and Stuart Mealing
Publication date: January 2026
Journal: Journal of Health Economics and Outcomes Research

Abstract

BACKGROUND: Infections represent the most serious complication associated with cardiac implantable electronic devices (CIEDs). This can result in prolonged hospital stays, high morbidity and mortality, and a significant economic burden for healthcare systems.

OBJECTIVES: This study aimed to evaluate the cost-effectiveness of the TYRX absorbable antibacterial envelope for CIED infection prevention from the Spanish Healthcare System perspective.

METHODS: A decision tree model with a lifetime horizon was developed to compare standard antibiotic prophylaxis with its combination with TYRX, regardless of infection risk. The model incorporated infection incidence, mortality, and utility values up to 36 months, derived from REINFORCE, AdaptResponse, and WRAP-IT studies. Unit costs (2025 euros) included prevention strategies and infection management. Lifetime costs and quality-adjusted life-years (QALYs) were assigned to survivors beyond 36 months. The incremental cost-effectiveness ratio (ICER) was reported by CIED and weighted by implant distribution (permanent pacemaker [PPM, 76.5%], implantable cardioverter-defibrillator [ICD, 15.2%], cardiac resynchronization therapy with defibrillator [CRT-D, 5.4%], and pacemaker [CRT-P, 2.9%]). A subgroup analysis was performed in high-risk patients (PADIT≥7), modifying infection rates based on PADIT risk stratification, along with sensitivity analyses. Model inputs were validated by an expert panel.

RESULTS: TYRX was the dominant strategy (more effective and less costly) for CRT-D and ICD recipients and cost-effective for those receiving PPM (€17 740/QALY) or CRT-P (€14 647/QALY), considering a willingness-to-pay threshold of €25 000/QALY. Across the spectrum of CIEDs, the ICER was €11 709/QALY. TYRX remained cost-effective in 77% of sensitivity analysis simulations. In high-risk patients, TYRX was dominant for all CIEDs.

DISCUSSION: This study is believed to be the first economic evaluation of TYRX in Spain and provides novel evidence in a broad, unselected population. Previous cost-effectiveness analyses conducted across different healthcare systems have consistently shown that TYRX is cost-effective in patients at elevated risk for device-related infections. Although the populations and healthcare settings differ, our findings are consistent with this body of evidence.

CONCLUSIONS: TYRX represents a dominant strategy for infection prevention for CRT-D and ICD and is cost-effective for PPM and CRT-P, based on Spain’s willingness to pay.

Peer-reviewed publication

Pharmaceutical Pollution from Health Care: A Systems-Based Strategy for Mitigating Risks to Public and Environmental Health

YHEC authors: Hayden Holmes, Matthew Taylor, Melissa Pegg
Publication date: January 2026
Publishers: The Lancet
Journal: The Lancet Planetary Health
Peer-reviewed publication

Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective

YHEC authors: Samuel Harper, Stuart Mealing
Publication date: January 2026
Journal: PharmacoEconomics Open

Abstract

BACKGROUND: Gastroesophageal reflux disease (GERD) affects 6.8 million individuals in Spain, incurring €56 million/year in healthcare costs. Standard-of-care treatment (SOC) in Spain includes medical management with proton pump inhibitors (PPIs) and laparoscopic Nissen fundoplication (LNF) in selected cases. The limitations of PPIs, including high rates of unresponsiveness, adverse events (AEs) associated with long-term use, and nonindicative misuse, increase the economic strain on European healthcare systems. The durability of LNF treatment is hindered by reoperation and postoperative complications. RefluxStop, a novel implantable device, restores the anti-reflux barrier without encircling the esophagus and confers long-term efficacy and safety in the treatment of GERD.

OBJECTIVE: This study assessed the cost-effectiveness of RefluxStop compared with medical (PPI-based) and surgical (LNF) SOC for refractory GERD in Spain.

METHODS: The cost-effectiveness of RefluxStop versus PPI-based medical management and LNF was assessed from the Spanish National Health System (SNS) perspective over a lifetime horizon (monthly cycles, 3.0% annual discount rate). A Markov model adapted from a published UK National Health Service (NHS) cost-effectiveness analysis of this device was used. Quality-adjusted life years (QALYs) and total costs were calculated for each intervention, while inter-arm differences were evaluated using incremental cost-effectiveness ratios (ICERs).

RESULTS: RefluxStop yielded ICERs of €557 and €2393 per QALY gained compared with medical management and LNF, respectively. At the cost-effectiveness threshold of €30,000 per QALY gained for Spain, the probability of RefluxStop being cost-effective was 100% compared with medical management and 93% compared with LNF. Over a lifetime horizon, the per-patient cost differences and QALY gains for RefluxStop were €1472 and 2.64 versus medical management and €2111 and 0.88 versus LNF, respectively. The model results remained robust to sensitivity analysis.

CONCLUSIONS: RefluxStop was estimated to be cost-effective relative to SOC in Spanish healthcare settings for the treatment of adult patients with refractory GERD, consistent with recently published findings in the UK, Switzerland, Sweden, and Norway. It is acknowledged that the model has limitations, including its reliance on single-arm trial data and indirect comparisons using heterogeneous literature sources, which limit the precision and generalizability of its findings.

Peer-reviewed publication

Health Economic Model to Evaluate the Cost-Effectiveness of Smoking Cessation Services Integrated Within Lung Cancer Screening in the United Kingdom

YHEC authors: Robert Malcolm, Hayden Holmes, Matthew Taylor
Publication date: January 2026
Publishers: BMJ Group
Journal: BMJ Thorax

Abstract

INTRODUCTION: Integrating smoking cessation supports into lung cancer screening can improve abstinence rates. However, healthcare decision-makers need evidence of cost-effectiveness to understand the cost/benefit of adopting this approach.

METHODS: To evaluate the cost-effectiveness of smoking cessation interventions, and service delivery, we used a cohort-based Markov model, adapted from previous National Institute for Health and Care Excellence (NICE) guidelines on smoking cessation. This uses long-term epidemiological data to capture the prevalence of the smoking-related illnesses, updated through targeted literature searches as required from the core NICE model, with costs extracted from publicly recognised UK sources.

RESULTS: All smoking cessation interventions appeared cost-effective at a threshold of £20 000 per quality-adjusted life year, compared with no intervention or behavioural support alone. Offering immediate smoking cessation as part of lung cancer screening appointments, compared with usual care (onward referral to stop smoking services), was also estimated to be cost-effective with a net monetary benefit of £2198 per person, and a saving of between £34 and £79 per person in reduced workplace absenteeism among working age attendees. Estimated healthcare cost savings were more than four times greater in the most deprived quintile compared with the least deprived, alongside a fivefold increase in quality adjusted life years accrued.

CONCLUSIONS: Smoking cessation interventions within lung cancer screening are cost-effective and should be integrated, so that treatment is initiated during screening visits. This is likely to reduce overall costs to the health service, and wider integrated care systems, improve quality and length of life, and may lessen health inequalities.

Peer-reviewed publication

Exploring the Economic Potential of Tellmi: A Novel Digital Mental Health Support App for Children and Young Adults

YHEC authors: Laura Kelly, Hayden Holmes, Charlotte Graham
Publication date: December 2025
Publishers: BMJ Group
Journal: BMJ Paediatrics Open

Abstract

BACKGROUND: Digital peer support apps can assist with mental ill health. We present an early economic evaluation of Tellmi, a related and novel app for children and young people (CYP).

METHODS: Tellmi users were surveyed; healthcare resource use over 3 months was captured. Data informed the development of an early cost-comparison model, capturing cost and resource use differences (CYP using Tellmi vs standard care). A 1-year time horizon was used, and the model was built from a National Health Service (NHS) perspective. Deterministic sensitivity analysis highlighted key driving parameters.

RESULTS: There were 283 responses. Tellmi use for more than 1 month resulted in significantly fewer accident and emergency, general practitioner and school nurses/counsellor visits (vs standard care). An early cost calculator model estimated that Tellmi use led to an NHS cost saving of £214 per person (excluding service cost).

CONCLUSIONS: Tellmi has the potential to be cost saving to the NHS. Further evidence is needed.

Peer-reviewed publication

Sjögren’s Hands-On Practice Exchange (SHAPE): A Qualitative, Expert Opinion Project in Sjögren’s Disease Clinical Practice

YHEC authors: Emily Gregg, Charlotte Graham, Deborah Watkins, Rachael McCool
Publication date: December 2025
Publishers: BMJ Group
Journal: BMC Rheumatology

Abstract

BACKGROUND: Sjögren’s disease (SjD) is a multifaceted, systemic autoimmune disease with substantial clinical heterogeneity. The objective of this study was to conduct a qualitative expert opinion exercise to explore how SjD is assessed, evaluated and managed in international clinical practice.

METHODS: A qualitative research design was used to elicit the expert opinion of 8 clinicians. Two researchers interviewed each clinician individually. The results of the interviews were synthesised using thematic analysis, and draft definitions of key terms were prepared. A group workshop was held to discuss/validate the interview results and refine the working definitions.

RESULTS: The clinicians had extensive experience in managing SjD from different countries. Seven topics emerged as major themes: disease classification, disease activity, relevant subpopulations, disease severity, disease progression, disease remission, and unmet needs. For 4 of these topics, there was no consensus – particularly regarding definitions that could be used in a clinical setting. The terms “systemic involvement” and “extra-glandular symptoms” have similar meanings but lack consistent application between clinicians. There was a lack of consensus on what “severity” refers to – whether it is severity of disease damage, the nature of disease manifestations, the potential for irreversible damage, or level of symptoms. There were also conflicting opinions regarding whether patient perspectives should be incorporated in key definitions.

CONCLUSION: There is currently a lack of standard definitions specifically for daily practice, which may contribute to high variability in clinical assessment and management. The definitions proposed in this study represent initial working concepts and are intended as a first step to promote further discussion among SjD experts to facilitate a more unified routine evaluation of patients.

Publication

Economic Evaluation of the TriageHF Plus Clinical Pathway for Device-Based Remote Monitoring in Heart Failure

YHEC authors: Sarah Medland, Daniela Afonso, Stuart Mealing
Publication date: December 2025
Publishers: BMJ Group
Journal: Heart

Abstract

BACKGROUND: In 2024, the UK National Institute of Health and Care Excellence (NICE) recommended TriageHF alerts as an option for remote monitoring of patients with heart failure (HF) and a compatible cardiac implantable electronic device (CIED). Data on the cost-effectiveness of this approach has not been published. This research evaluates the cost-effectiveness of TriageHF Plus in public hospital settings, using data from the TriageHF Plus multicentre study (758 participants, NCT04177199).

METHODS: An economic model was developed to capture the lifetime cost and benefits of TriageHF Plus versus usual care, based on a site of 300 eligible patients. Analysis on individual patient-level data informed model efficacy and resource use parameters. EuroQol five-dimensional questionnaire data and unit costs were obtained from published, peer-reviewed literature and national databases respectively. Costs and benefits were discounted at 3.5% per annum to adjust future costs and benefits to present value.

RESULTS: In a site size of 300, TriageHF Plus was predicted to prevent 384 (363–405) hospitalisations over 5 years. In total, TriageHF Plus saved £3989 (£1812–£5563) per person-lifetime versus usual care and was more effective and cost-saving in 99.4% of simulations. Results were robust to changes in key input parameters. Modelling showed that to avoid one hospitalisation, 1.7 people would need lifetime access to TriageHF Plus.

CONCLUSION: The TriageHF Plus pathway is cost-effective for the remote monitoring of HF in patients with CIEDs.

1 … 4 5 6 7 8 … 83